


PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE



TITLE

: Formalities Letter dated January 10, 2002
(Confirmation No. 9776)

: METHODS FOR MAKING AND DELIVERING RHO-ANTAGONIST TISSUE ADHESIVE FORMULATIONS TO THE INJURED MAMMALIAN CENTRAL AND PERIPHERAL NERVOUS SYSTEMS AND USES THEREOF

APPLICANT/INVENTOR : MCKERRACHER, Lisa

FILED : November 30th, 2000

SERIAL NO. : 09/725,906

GROUP ART UNIT : 1615

ATTORNEY DOCKET NO: 06447-003-US-02

Montréal, Québec, Canada
February 18, 2002

RESPONSE

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

The present is in response to the Formalities Letter dated January 10, 2002, regarding the sequence listing requirements.

The Applicant respectfully submits that in a previous Response to an Office Letter dated March 6, 2001 and sent on August 2, 2001 to the USPTO, the Sequence Listing as well as every amino acid or nucleotide sequence disclosure was deleted from the application. Thereby, the Applicant should not be required to comply with the sequence listing requirements.

Respectfully submitted,
BROUILLETTE KOSIE

Ronald S. Kosie

Ronald S. Kosie
Reg. No. 28,814
1100 René-Lévesque Blvd West
25th Floor
Montréal, Québec
Canada H3B 5C9

Telephone: (514) 397-6942
Fax: (514) 397-8515

(Docket no. 06447-003-US-02)

Encl. Copy of USPTO notice
Confirmation receipt post card



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY/AGENT NUMBER
09/725,906	11/30/2000	Lisa McKerracher	06447-003-US-02



BROUILLETTE KOSIE
25th Floor
1100 Rene-Levesque Blvd. West
Montreal, QC H3B 5C9
CANADA

CONFIRMATION NO. 9776
FORMALITIES LETTER



OC00000007294175

Date Mailed: 01/10/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY